Drug Profile
Research programme: polysaccharideglycobiology therapeutics - GlycoMar
Alternative Names: GLY 2028Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator GlycoMar
- Class Antipsoriatics; Polysaccharides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Psoriasis in United Kingdom (Topical)
- 29 Jul 2016 Research programme: polysaccharideglycobiology therapeutics - GlycoMar is available for licensing - http://www.glycomar.com/partnerships.htm
- 29 Jul 2016 Preclinical trials in Psoriasis in United Kingdom (Topical)